Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Eur J Med Chem. 2023 Jun 5:254:115371. doi: 10.1016/j.ejmech.2023.115371. Epub 2023 Apr 15.

Abstract

The NaV1.8 channel is a genetically validated target for pain and it is mostly expressed in the peripheral nervous system. Based on the disclosed structures of NaV1.8-selective inhibitors, we designed and synthesized a series of compounds by introducing bicyclic aromatic fragments based on the nicotinamide scaffold. In this research, a systematic structure-activity relationship study was carried out. While compound 2c possessed moderate inhibitory activity (IC50 = 50.18 ± 0.04 nM) in HEK293 cells stably expressing human NaV1.8 channels, it showed potent inhibitory activity in DRG neurons and isoform selectivity (>200-fold against human NaV1.1, NaV1.5 and NaV1.7 channels). Moreover, the analgesic potency of compound 2c was identified in a post-surgical mouse model. These data demonstrate that compound 2c can be further evaluated as a non-addictive analgesic agent with reduced cardiac liabilities.

Keywords: Bicyclic aromatic groups; Na(V)1.8-selective inhibitors; Non-addictive analgesics; Pain.

MeSH terms

  • Analgesics / chemistry
  • Analgesics / pharmacology
  • Analgesics / therapeutic use
  • Animals
  • HEK293 Cells
  • Humans
  • Mice
  • NAV1.7 Voltage-Gated Sodium Channel*
  • Niacinamide* / pharmacology
  • Niacinamide* / therapeutic use
  • Pain / drug therapy

Substances

  • Niacinamide
  • NAV1.7 Voltage-Gated Sodium Channel
  • Analgesics